Literature DB >> 34525365

RORα is critical for mTORC1 activity in T cell-mediated colitis.

Xinxin Chi1, Wei Jin2, Xue Bai2, Xiaohong Zhao2, Jing Shao2, Jiaqi Li2, Qinli Sun2, Bing Su3, Xiaohu Wang2, Xuexian O Yang4, Chen Dong5.   

Abstract

Inflammatory bowel disease (IBD) is multi-factorial chronic intestinal inflammation driven by pathogenic T cells, among which a large portion of patients are resistant to current anti-inflammatory regimes. The mechanisms underlying colitis pathogenicity and drug resistance are not fully understood. Here, we demonstrate that RORα is highly expressed in active UC patients, particularly in those non-responsive to anti-TNF treatment. Rorα deficiency in CD4+ T cells greatly reduced colitis development. Mechanistically, RORα regulated T cell infiltration in colon and inhibited T cell apoptosis. Meanwhile, genome-wide occupancy and transcriptome analysis revealed that RORα promoted mTORC1 activation. mTORC1 signaling, also hyperactivated in active UC patients, is necessary for T cell-mediated colitis. Our results thus demonstrate a crucial role of the RORα-mTORC1 axis in CD4+ T cells in promoting IBD, which may be targeted in human patients.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD4(+) T cells; RORα; anti-TNF therapy; colitis; mTORC1

Mesh:

Substances:

Year:  2021        PMID: 34525365     DOI: 10.1016/j.celrep.2021.109682

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  2 in total

1.  Transcriptional Interactomic Inhibition of RORα Suppresses Th17-Related Inflammation.

Authors:  Chun-Chang Ho; Giha Kim; Chin Hee Mun; Ju-Won Kim; Jieun Han; Ji Yoon Park; Yong-Beom Park; Sang-Kyou Lee
Journal:  J Inflamm Res       Date:  2021-12-21

2.  Rora Regulates Neutrophil Migration and Activation in Zebrafish.

Authors:  Alan Y Hsu; Tianqi Wang; Ramizah Syahirah; Sheng Liu; Kailing Li; Weiwei Zhang; Jiao Wang; Ziming Cao; Simon Tian; Sandro Matosevic; Christopher J Staiger; Jun Wan; Qing Deng
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.